RxDoctor Payments Data

Linda Zacharias, MD

Rheumatology · Edmond, OKNPI 1861535908

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $959 of the $1,177 with a category attached, or 81.5%. 11 manufacturers reported payments, led by AbbVie at 37.7% of the total. That places this record below the midpoint for rheumatology clinicians in OK, where the typical reported total is $4,359.

$1,177in general payments, 2019–2025

Across 22 payments — averaging $53.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$444
  • Amgen$251
  • United Therapeutics Corporation$122
  • Lilly USA, LLC$120
  • E.r. Squibb & Sons, L.L.C.$108
  • GSK$33
  • plus $99 from 5 others

What the payments were for

  • Food & beverage$95982%
  • Education$21718%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,177 in reported general payments places this provider in the 30th percentile of 67 rheumatology providers in Oklahoma.

See all rheumatology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$110,910
Medicare patients
266
Services billed
3,093

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab22$303,625
Enbrel SureclickEtanercept22$238,037
RinvoqUpadacitinib33$229,884
Xeljanz XrTofacitinib Citrate33$190,376
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$171,434
BenlystaBelimumab21$82,344
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$44,305
Hydroxychloroquine Sulfate354$13,212
Cevimeline Hcl31$5,631
Duloxetine Hcl154$4,266
Pilocarpine Hcl52$3,701
MethotrexateMethotrexate Sodium132$3,549
Buprenorphine19$3,073
Leflunomide60$2,832
Mycophenolate Mofetil30$2,131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$444$229,88433 claims
GSKBenlysta$33$82,34421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 67 rheumatology providers in Oklahoma.

Other rheumatology in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →